Sixpex Arimidex

Pack&Dosage: 30 tabs (1 mg/tab)

Active Ingredient: Anastrozole

Brand: Sixpex

1. Introduction to Anastrozole

Aromatase is an enzyme that contributes to the production of the female hormone, estrogen. Many breast cancers are stimulated to grow by estrogen. These breast cancers are called estrogen-dependent. Abnormally high levels of estrogen can cause estrogen-dependent breast cancer to grow and eventually lead to relapse. Anastrozole is used to treat breast cancer in postmenopausal women. It is the first in a new class of powerful drugs designed to block high levels of estrogen and help prevent breast cancer relapse.

Anastrozole is a nonsteroidal and specific aromatase inhibitor. It caused a decrease in the level of circulating estrogen in postmenopausal women, but unlike tamoxifen, anastrozole had no estrogenic activity. Anastrozole was absorbed quickly and extensively when taken orally. When taken with food, bioavailability was too low. The steady-state concentration of circulating estrogen was achieved in 7 days, followed by a 90% suppression relative to baseline. In conclusion, anastrozole, orally administered, inhibits the level of circulating estrogen and is well tolerated in postmenopausal women.

1.1. Definition and Mechanism of Action

Anastrozole is a potent and highly selective reversible nonsteroidal aromatase inhibitor of the third generation of the benzyl triazole class. Anastrozole reduces the levels of serum estradiol by 92% from the initial value of the patient, which has a therapeutic effect in patients with tumors sensitive to hormone levels. Etiologically, all breast cancers develop under the influence of estrogens. After menopause, most secondary estrogen in women extends from aromatase in peripheral tissues. Anastrozole works by selectively inhibiting aromatase proteins. In postmenopausal women, reducing the level of estrogen delays the progression of the disease and significantly increases survival. The serum estrogen concentration remains within the postmenopausal range in 95% of the patients studied while receiving monotherapy of 1 mg daily. The combination of anastrozole with tamoxifen significantly reduced the estradiol levels by approximately 30% at the time of the examination compared with users of anastrozole or tamoxifen. In the total rate, alkaline phosphatase and aminotransferase increased in patients with breast cancer in one or both treatment groups. However, such findings were rare, and such increases were more obvious in the tamoxifen group.